re: Ann: Change of Director's Interest No... Rare stuff attracts orphan status attracts quicker (smaller trials etc) and longer commercialisation.
I think it's a good strategy for capital constrained microcap Biotechs.
Among other things I'm impressed with the longevity of their IP, especially given their two most advanced drugs are mid to late stage.
If things go to plan they will have well over 10 years exclusivity in the market.
re: Ann: Change of Director's Interest No... Rare stuff attracts...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
